trending Market Intelligence /marketintelligence/en/news-insights/trending/vwVbmacmJ3G84FRpUFkH2A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sanofi kicks off tender offer to acquire Synthorx for $2.5B

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Sanofi kicks off tender offer to acquire Synthorx for $2.5B

Sanofi began its tender offer to acquire all common shares of immuno-oncology company Synthorx Inc. at $68 each.

The deal is valued at $2.5 billion, and the acquisition is expected to boost French drugmaker Sanofi's oncology and immuno-oncology pipeline with Synthorx's lead asset, THOR-707, which is being studied as a potential treatment for multiple solid tumor types.

Sanofi's offer is expected to expire Jan. 22, 2020.

Morgan Stanley & Co. is acting as financial adviser to Sanofi, with Weil Gotshal & Manges LLP serving as legal counsel. Centerview Partners LLC is the exclusive financial adviser to Synthorx, while Cooley LLP is acting as legal counsel.